Treatment to keep dialysis fistulas open
Development of a Treatment to Improve Arteriovenous Fistula Function
['FUNDING_SBIR_2'] · PAVAJ VASCULAR CORPORATION · NIH-11194473
A local nanoparticle therapy delivering active vitamin D aims to stop vein narrowing in people who use arteriovenous fistulas for hemodialysis.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PAVAJ VASCULAR CORPORATION (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-11194473 on ClinicalTrials.gov |
What this research studies
This project is developing a way to deliver the active form of vitamin D directly around the dialysis fistula using biodegradable nanoparticles to block genes that drive vein thickening. Researchers have studied human fistula tissue and tested the approach in animal models that show reduced venous stenosis. The current work focuses on optimizing the nanoparticle delivery and safety so the therapy could move toward use in people. If safe and effective, the therapy would be tested at clinical sites for people receiving hemodialysis via an AV fistula.
Who could benefit from this research
Good fit: People with end-stage kidney disease who use an arteriovenous fistula for hemodialysis—especially those with new or failing fistulas—would be the ideal candidates.
Not a fit: People who do not use an AV fistula for dialysis (for example those using catheters or grafts) or whose problems are unrelated to venous neointimal hyperplasia may not benefit.
Why it matters
Potential benefit: If successful, the therapy could reduce vein narrowing and lower the need for repeated procedures to keep dialysis fistulas working.
How similar studies have performed: Laboratory and animal studies support the biological target, but delivering active vitamin D locally via nanoparticles is a novel approach that has not yet been proven in people.
Where this research is happening
ROCHESTER, UNITED STATES
- PAVAJ VASCULAR CORPORATION — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MILLER, AARON — PAVAJ VASCULAR CORPORATION
- Study coordinator: MILLER, AARON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.